Evidence map›Paper›PMID 36254536›Full record

ReviewTechnology in cancer research & treatment

CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Fatima Akram, Ikram Ul Haq, Sania Sahreen, Narmeen Nasir, Waqas Naseem, Memoona Imitaz, Amna Aqeel

RetractedAbstract readReviewRetracted Publication
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Fatima AkramInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.ORCID 0000-0001-8438-706X
Ikram Ul HaqInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.
Sania SahreenInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.
Narmeen NasirInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.
Waqas NaseemInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.
Memoona ImitazInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.
Amna AqeelInstitute of Industrial Biotechnology, 66878Government College University, Lahore, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a genetic disease stemming from genetic and epigenetic mutations and is the second most common cause of death across the globe. Clustered regularly interspaced short palindromic repeats (CRISPR) is an emerging gene-editing tool, acting as a defense system in bacteria and archaea. CRISPR/Cas9 technology holds immense potential in cancer diagnosis and treatment and has been utilized to develop cancer disease models such as medulloblastoma and glioblastoma mice models. In diagnostics, CRISPR can be used to quickly and efficiently detect genes involved in various cancer development, proliferation, metastasis, and drug resistance. CRISPR/Cas9 mediated cancer immunotherapy is a well-known treatment option after surgery, chemotherapy, and radiation therapy. It has marked a turning point in cancer treatment. However, despite its advantages and tremendous potential, there are many challenges such as off-target effects, editing efficiency of CRISPR/Cas9, efficient delivery of CRISPR/Cas9 components into the target cells and tissues, and low efficiency of HDR, which are some of the main issues and need further research and development for completely clinical application of this novel gene editing tool. Here, we present a CRISPR/Cas9 mediated cancer treatment method, its role and applications in various cancer treatments, its challenges, and possible solution to counter these challenges.

Indexed as

Gene EditingNeoplasmsAnimalsCRISPR-Cas SystemsGenetic TherapyHumansImmunotherapyMicecancerCRISPR/Cas9diagnosisgene editingimmunotherapy

Identifiers

PMID36254536
PMCPMC9580090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.